Biotech: 9 new Made in Italy projects on health and environmental sustainability

The nine finalist projects of the XIV edition of the BioInItaly Investment Forum & Intesa Sanpaolo Start-Up Initiative – the investment forum of reference for innovation in biotechnology and life sciences in Italy – were selected from the Investor Arena meeting held on 8 April.

Since 2008, the BioInItaly Investment Forum has made possible the investment of over €70 million in support of biotech start-ups and SMEs.

The innovative Made in Italy biotech finalists of the BioInItaly Forum 2021 presented projects ranging from the development of technologies for sustainable encapsulation, to plants that become bioreactors to produce sustainable biopharmaceuticals, through innovative therapies for autoimmune diseases and myeloid disorders, bioremediation services and recovery of contaminated and degraded land thanks to a mix of robotics, wireless devices and biotechnology.

BioInItaly Investment Forum is a reference point for innovative companies in the life sciences and circular economy sector. For 14 years, the path organised by Intesa Sanpaolo Innovation Center, Assobiotec and Cluster Spring has allowed innovative biotech companies and business projects in need of funding to meet investors from all over the world.

The partners of the BioInItaly Investment Forum & Intesa Sanpaolo Start-Up Initiative 2021 edition were: Ellen MacArthur Foundation, Novamont, Stifel, LCA, Goodwin, Ayming, Human Technopole and Bird & Bird and with the endorsement of ICE/ITA – Italian Trade Agency and Invitalia.